Drugs / rhKGF-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07558538 | May → Nov 2026 expected | acute respiratory distress syndrome | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rh-KGF-2 | “A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2...” NCT07558538 ↗1“This study is a randomized, blank-controlled, open-label, single-dose, dose-escalation clinical study of rhKGF-2 in patients with ARDS.” NCT07558538 ↗ |
| Known as | Recombinant Human Keratinocyte Growth Factor-2 | “A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2...” NCT07558538 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Keratinocyte Growth Factor-2 for Inhalation (Lyophilized Powder)” NCT07558538 ↗ |
| Route | Inhaled | “Recombinant Human Keratinocyte Growth Factor-2 for Inhalation (Lyophilized Powder)” NCT07558538 ↗ |